Yong Fang1, Jun-Jie Cen1, Jia-Zheng Cao2, Yong Huang1, Zi-Hao Feng1, Jun Lu1, Jin-Huan Wei1, Zhen-Hua Chen1, Yan-Ping Liang1, Bing Liao3, Jun-Hang Luo1, Wei Chen1. 1. Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, PR China. 2. Department of Urology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen 529030, PR China. 3. Department of Pathology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, PR China.
Abstract
Aim: To study the expression of EIF5A2 in urinary tract urothelial carcinoma and its clinicopathological features and prognosis. Methods: EIF5A2 expression was detected via immunohistochemistry in 101 patients. Results: Kaplan-Meier analysis showed that the EIF5A2 low expression group had significantly longer overall survival (OS; p < 0.001) and progression-free survival (PFS; p < 0.001) than the EIF5A2 high expression group. The high expression of EIF5A2 significantly predict poor OS and PFS in the subset patients (p < 0.05). EIF5A2 was an independent prognostic factor for OS and PFS (p = 0.003 and p = 0.001). The established nomogram model and its calibration curve predicted the probability of survival accurately. Conclusion: EIF5A2 is a potential molecular marker of poor prognosis in urinary tract urothelial carcinoma.
Aim: To study the expression of EIF5A2 in urinary tract urothelial carcinoma and its clinicopathological features and prognosis. Methods:EIF5A2 expression was detected via immunohistochemistry in 101 patients. Results: Kaplan-Meier analysis showed that the EIF5A2 low expression group had significantly longer overall survival (OS; p < 0.001) and progression-free survival (PFS; p < 0.001) than the EIF5A2 high expression group. The high expression of EIF5A2 significantly predict poor OS and PFS in the subset patients (p < 0.05). EIF5A2 was an independent prognostic factor for OS and PFS (p = 0.003 and p = 0.001). The established nomogram model and its calibration curve predicted the probability of survival accurately. Conclusion:EIF5A2 is a potential molecular marker of poor prognosis in urinary tract urothelial carcinoma.